Difference between revisions of "Main Page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "http://en.wikipedia.org" to "https://en.wikipedia.org")
 
(95 intermediate revisions by the same user not shown)
Line 1: Line 1:
−
<div style="text-align:left; border: 20px solid #000000; padding: 5px; font-size:100%">
 
−
'''Thank you for visiting HemOnc.org. Given the unprecedented COVID-19 pandemic, we are taking this space on the landing page to ask you to consider the following:
 
−
#'''Visit our [[COVID-19 coronavirus and cancer|COVID-19 page]] for information on the outbreak, guidance for clinicians, emerging literature, etc.
 
−
#'''Contribute cases of cancer patients with suspected or confirmed infection to the [https://www.ccc19.org COVID-19 and Cancer Consortium (CCC19) Registry]
 
−
</div>
 
−
 
 
{{DISPLAYTITLE:<span style="display: none"></span>}}
 
{{DISPLAYTITLE:<span style="display: none"></span>}}
 
__NOTOC__  
 
__NOTOC__  
Line 12: Line 6:
 
</div>
 
</div>
  
−
<div style="text-align:center"><big>HemOnc.org is the largest freely available medical wiki of [[:Category:Intervention_index|interventions]], [[:Category:Regimen_index|regimens]], and [[:Category:General_reference_pages|general information]] relevant to the fields of hematology and oncology. It is designed for easy use and intended for healthcare professionals. Any healthcare professional can [[How to contribute|sign up to contribute]]; the [[Eligibility criteria|accuracy and completeness of content]] is overseen by the [[Editorial Board]]. Heavily visited pages can be accessed directly from the menu on the left. If this is your first time visiting, please '''[[Tutorial|go to the tutorial page]]''' or just start exploring!</big></div>
+
<div style="text-align:center"><big>HemOnc.org is the largest freely available medical wiki of [[:Category:Intervention_index|interventions]], [[:Category:Regimen_index|regimens]], and [[:Category:General_reference_pages|general information]] relevant to the fields of hematology and oncology. Any healthcare professional can [[How to contribute|sign up to contribute]]; the [[Eligibility criteria|accuracy and completeness of content]] is overseen by the [[Editorial Board]]. Heavily visited pages can be accessed directly from the menu on the left. If this is your first time visiting, please start with the '''[[Tutorial|the tutorial page]]''', review our '''[[philosophy]]''', or just start exploring!</big></div>
  
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
 
|-
 
|-
−
!colspan="6" style="font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimens|<span style="color:black;">Regimens</span>]]: {{#ask: [[Regimen::+]] |?Regimen|limit=10000|format=sum}}
+
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimens|<span style="color:black;">Regimens</span>]]: 5,262
−
!colspan="6" style="font-size:150%; background-color:#bdbdbd"|[[Tutorial#Variants|<span style="color:black;">Regimen variants</span>]]: {{#ask: [[Variant::+]] |?Variant|limit=10000|format=sum}}
+
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:#3c0008;">Guidelines: 1,217</span>
 +
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">Studies</span>: 6,769
 +
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">References</span>: 7,731
 
|-
 
|-
−
|colspan="3" style="width: 25%; font-size:125%; background-color:#08519c"|[[#solidtumors|<span style="color:white;">Solid Tumors</span>]]
+
|}
−
|colspan="3" style="width: 25%; font-size:125%; background-color:#de2d26"|[[#malignantheme|<span style="color:white;">Malignant Hematology</span>]]
+
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
−
|colspan="3" style="width: 25%; font-size:125%; background-color:#4a1486"|[[#transplant|<span style="color:white;">Cross-Disciplinary</span>]]
 
−
|colspan="3" style="width: 25%; font-size:125%; background-color:#31a354"|[[#classicalheme|<span style="color:white;">Classical Hematology</span>]]
 
 
|-
 
|-
−
|colspan="6" style="width: 17.5%; background-color:#636363"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_mobile <span style="color:white;">Mobile Version</span>]'''
+
|style="width: 20%; font-size:125%; background-color:#08519c"|[[#solidtumors|<span style="color:white;">Solid Tumors</span>]]
−
|colspan="6" style="width: 17.5%; background-color:#636363"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_desktop <span style="color:white;">Desktop Version</span>]'''
+
|style="width: 20%; font-size:125%; background-color:#de2d26"|[[#malignantheme|<span style="color:white;">Malignant Hematology</span>]]
 +
|style="width: 20%; font-size:125%; background-color:#ba871a"|[[#peds|<span style="color:white;">Pediatrics</span>]]
 +
|style="width: 20%; font-size:125%; background-color:#4a1486"|[[#transplant|<span style="color:white;">Transplant & IEC</span>]]
 +
|style="width: 20%; font-size:125%; background-color:#31a354"|[[#classicalheme|<span style="color:white;">Classical Hematology</span>]]
 
|-
 
|-
 
|}  
 
|}  
Line 39: Line 36:
 
|style="background-color:#deebf7"|[[Breast cancer, ER-positive]]
 
|style="background-color:#deebf7"|[[Breast cancer, ER-positive]]
 
|style="background-color:#deebf7"|[[Breast cancer, HER2-positive]]
 
|style="background-color:#deebf7"|[[Breast cancer, HER2-positive]]
 +
|style="background-color:#deebf7"|[[Breast cancer, ER and HER2 co-expressing]]
 +
|-
 
|style="background-color:#deebf7"|[[Breast cancer, triple negative|Breast cancer, triple negative (TNBC)]]
 
|style="background-color:#deebf7"|[[Breast cancer, triple negative|Breast cancer, triple negative (TNBC)]]
−
|-
 
 
|style="background-color:#deebf7"|[[Breast cancer, BRCA-mutated]]
 
|style="background-color:#deebf7"|[[Breast cancer, BRCA-mutated]]
 
|style="background-color:#deebf7"|[[Breast cancer, PIK3CA-mutated]]
 
|style="background-color:#deebf7"|[[Breast cancer, PIK3CA-mutated]]
−
|style="background-color:#deebf7"|
 
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
Line 55: Line 52:
 
|style="background-color:#deebf7"|[[Melanoma,_KIT-mutated|Melanoma, KIT-mutated]]  
 
|style="background-color:#deebf7"|[[Melanoma,_KIT-mutated|Melanoma, KIT-mutated]]  
 
|style="background-color:#deebf7"|[[Melanoma,_NRAS-mutated|Melanoma, NRAS-mutated]]  
 
|style="background-color:#deebf7"|[[Melanoma,_NRAS-mutated|Melanoma, NRAS-mutated]]  
−
|style="background-color:#deebf7"|[[Merkel cell carcinoma]]  
+
|style="background-color:#deebf7"|[[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]]  
 
|style="background-color:#deebf7"|[[Uveal melanoma]]  
 
|style="background-color:#deebf7"|[[Uveal melanoma]]  
 
|-
 
|-
Line 61: Line 58:
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Adrenocortical carcinoma]]
 
|style="background-color:#deebf7"|[[Adrenocortical carcinoma]]
−
|style="background-color:#deebf7"|[[Neuroendocrine tumor]]
+
|style="background-color:#deebf7"|[[Neuroendocrine tumor|Neuroendocrine tumor (NET)]]
 +
|style="background-color:#deebf7"|[[Neuroendocrine carcinoma|Neuroendocrine carcinoma (NEC)]]
 
|style="background-color:#deebf7"|[[Pancreatic NET]]
 
|style="background-color:#deebf7"|[[Pancreatic NET]]
 +
|-
 
|style="background-color:#deebf7"|[[Pheochromocytoma]]
 
|style="background-color:#deebf7"|[[Pheochromocytoma]]
 +
|style="background-color:#deebf7"|[[Thyroid cancer]]
 +
|style="background-color:#deebf7"|[[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]]
 +
|style="background-color:#deebf7"|[[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]]
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Thyroid cancer]]
 
 
|style="background-color:#deebf7"|[[Thyroid_cancer,_BRAF-mutated|Thyroid cancer, BRAF-mutated]]
 
|style="background-color:#deebf7"|[[Thyroid_cancer,_BRAF-mutated|Thyroid cancer, BRAF-mutated]]
 
|style="background-color:#deebf7"|[[Thyroid_cancer,_RET-positive|Thyroid cancer, RET-positive]]
 
|style="background-color:#deebf7"|[[Thyroid_cancer,_RET-positive|Thyroid cancer, RET-positive]]
 +
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology, Intestinal'''
 
|-
 
|-
 
|style="width: 25%; background-color:#deebf7"|[[Anal cancer]]
 
|style="width: 25%; background-color:#deebf7"|[[Anal cancer]]
−
|style="width: 25%; background-color:#deebf7"|[[Cholangiocarcinoma]]
+
|style="width: 25%; background-color:#deebf7"|[[Appendiceal tumor]]
 
|style="width: 25%; background-color:#deebf7"|[[Colon cancer]]
 
|style="width: 25%; background-color:#deebf7"|[[Colon cancer]]
−
|style="width: 25%; background-color:#deebf7"|[[Colon cancer, BRAF-mutated]]
+
|style="width: 25%; background-color:#deebf7"|[[Colon cancer, RAS wild-type]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Colon cancer, HER2-positive]]
+
|style="width: 25%; background-color:#deebf7"|[[Colorectal cancer|Colorectal cancer (CRC)]]
−
|style="width: 25%; background-color:#deebf7"|[[Colon cancer, KRAS wild-type]]
+
|style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, BRAF-mutated|CRC, BRAF-mutated]]
 +
|style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, HER2-positive|CRC, HER2-positive]]
 +
|style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, MSI-H or dMMR|CRC, MSI-H or dMMR]]
 +
|-
 +
|style="width: 25%; background-color:#deebf7"|[[Colorectal cancer, RAS wild-type|CRC, RAS wild-type]]
 
|style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]]
 
|style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]]
−
|style="width: 25%; background-color:#deebf7"|[[Gallbladder cancer]]
+
|style="width: 25%; background-color:#deebf7"|[[Esophageal adenocarcinoma]]
 +
|style="width: 25%; background-color:#deebf7"|[[Esophageal squamous cell carcinoma|Esophageal SCC]]
 
|-
 
|-
 
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer]]
 
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer]]
 
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer, HER2-positive]]
 
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer, HER2-positive]]
−
|style="width: 25%; background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
+
|style="width: 25%; background-color:#deebf7"|[[Rectal cancer]]
−
|style="width: 25%; background-color:#deebf7"|[[Hepatocellular carcinoma]]
+
|style="width: 25%; background-color:#deebf7"|[[Small bowel adenocarcinoma]]
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology, Extraintestinal'''
 
|-
 
|-
 +
|style="width: 25%; background-color:#deebf7"|[[Cholangiocarcinoma]]
 +
|style="width: 25%; background-color:#deebf7"|[[Gallbladder cancer]]
 +
|style="width: 25%; background-color:#deebf7"|[[Hepatocellular carcinoma|Hepatocellular carcinoma (HCC)]]
 
|style="width: 25%; background-color:#deebf7"|[[Periampullary adenocarcinoma]]
 
|style="width: 25%; background-color:#deebf7"|[[Periampullary adenocarcinoma]]
−
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer]]  
+
|-
−
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer, BRCA-mutated]]
+
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer|Pancreatic adenocarcinoma]]  
 +
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer, BRCA-mutated|Pancreatic adenocarcinoma, BRCA-mutated]]
 
|style="width: 25%; background-color:#deebf7"|[[Pancreatic NET]]
 
|style="width: 25%; background-color:#deebf7"|[[Pancreatic NET]]
−
|-
 
−
|style="width: 25%; background-color:#deebf7"|[[Rectal cancer]]
 
−
|style="background-color:#deebf7"|
 
−
|style="background-color:#deebf7"|
 
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Genitourinary Oncology'''
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Genitourinary Oncology'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Bladder cancer]]
 
 
|style="background-color:#deebf7"|[[Penile cancer]]
 
|style="background-color:#deebf7"|[[Penile cancer]]
 
|style="background-color:#deebf7"|[[Prostate cancer]]
 
|style="background-color:#deebf7"|[[Prostate cancer]]
 +
|style="background-color:#deebf7"|[[Prostate cancer, BRCA-mutated]]
 +
|style="background-color:#deebf7"|[[Testicular cancer]]
 +
|-
 
|style="background-color:#deebf7"|[[Renal cell carcinoma|Renal cell carcinoma (RCC)]]
 
|style="background-color:#deebf7"|[[Renal cell carcinoma|Renal cell carcinoma (RCC)]]
 +
|style="background-color:#deebf7"|[[Clear cell renal cell carcinoma|Clear cell RCC (ccRCC)]]
 +
|style="background-color:#deebf7"|[[Non-clear cell renal cell carcinoma|Non-clear cell RCC (nccRCC)]]
 +
|style="background-color:#deebf7"|[[Papillary renal cell carcinoma|Papillary RCC]]
 +
|-
 +
|style="background-color:#deebf7"|[[Sarcomatoid renal cell carcinoma|Sarcomatoid RCC]]
 +
|style="background-color:#deebf7"|[[Renal_cell_carcinoma,_VHL-associated|VHL-associated RCC]]
 +
|style="background-color:#deebf7"|
 +
|style="background-color:#deebf7"|
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Testicular cancer]]
+
|style="background-color:#deebf7"|[[Urothelial carcinoma]]
 +
|style="background-color:#deebf7"|[[Bladder cancer]]
 
|style="background-color:#deebf7"|[[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]]
 
|style="background-color:#deebf7"|[[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]]
−
|style="background-color:#deebf7"|
 
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
Line 114: Line 133:
 
|style="background-color:#deebf7"|[[Endometrial cancer]]
 
|style="background-color:#deebf7"|[[Endometrial cancer]]
 
|style="background-color:#deebf7"|[[Gestational trophoblastic neoplasia]]
 
|style="background-color:#deebf7"|[[Gestational trophoblastic neoplasia]]
 +
|style="background-color:#deebf7"|[[Low-grade serous ovarian cancer|Low-grade serous ovarian cancer (LGSOC)]]
 +
|-
 
|style="background-color:#deebf7"|[[Ovarian cancer]]
 
|style="background-color:#deebf7"|[[Ovarian cancer]]
−
|-
 
 
|style="background-color:#deebf7"|[[Ovarian cancer, BRCA-mutated]]
 
|style="background-color:#deebf7"|[[Ovarian cancer, BRCA-mutated]]
 
|style="background-color:#deebf7"|[[Vulvar cancer]]
 
|style="background-color:#deebf7"|[[Vulvar cancer]]
−
|style="background-color:#deebf7"|
 
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
Line 124: Line 143:
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Head and neck cancer]]
 
|style="background-color:#deebf7"|[[Head and neck cancer]]
−
|style="background-color:#deebf7"|[[Nasopharyngeal carcinoma]]
+
|style="background-color:#deebf7"|[[Nasopharyngeal carcinoma|Nasopharyngeal carcinoma (NPC)]]
 
|style="background-color:#deebf7"|[[Oropharyngeal_cancer,_HPV-positive|HPV+ Oropharyngeal cancer]]
 
|style="background-color:#deebf7"|[[Oropharyngeal_cancer,_HPV-positive|HPV+ Oropharyngeal cancer]]
−
|style="background-color:#deebf7"|[[Thyroid cancer]]
+
|style="background-color:#deebf7"|
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Mesothelioma'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Thyroid_cancer,_BRAF-mutated|Thyroid cancer, BRAF-mutated]]
+
|colspan="2" style="background-color:#deebf7"|[[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]]
−
|style="background-color:#deebf7"|
+
|colspan="2" style="background-color:#deebf7"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]]
−
|style="background-color:#deebf7"|
 
−
|style="background-color:#deebf7"|
 
 
|-
 
|-
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Neuro-Oncology'''
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Neuro-Oncology'''
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Anaplastic glioma]]
 
|style="background-color:#deebf7"|[[Anaplastic glioma]]
−
|style="background-color:#deebf7"|[[Glioblastoma]]
+
|style="background-color:#deebf7"|[[Craniopharyngioma]]
 +
|style="background-color:#deebf7"|[[Glioblastoma|Glioblastoma (GBM)]]
 
|style="background-color:#deebf7"|[[Low-grade glioma]]
 
|style="background-color:#deebf7"|[[Low-grade glioma]]
 +
|-
 
|style="background-color:#deebf7"|[[Meningioma]]
 
|style="background-color:#deebf7"|[[Meningioma]]
 +
|style="background-color:#deebf7"|[[Subependymal giant cell astrocytoma|Subependymal giant cell astrocytoma (SEGA)]]
 +
|style="background-color:#deebf7"|
 +
|style="background-color:#deebf7"|
 
|-
 
|-
 
|style="background-color:#deebf7"|[[CNS carcinoma]]
 
|style="background-color:#deebf7"|[[CNS carcinoma]]
Line 147: Line 171:
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Sarcoma'''
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Sarcoma'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Bone sarcoma]]  
+
|style="background-color:#deebf7"|[[Bone sarcoma]]
 
|style="background-color:#deebf7"|[[Ewing sarcoma]]
 
|style="background-color:#deebf7"|[[Ewing sarcoma]]
 +
|style="background-color:#deebf7"|[[Giant-cell tumor of bone]]
 +
|style="background-color:#deebf7"|[[Osteosarcoma]]
 +
|-
 +
|style="background-color:#deebf7"|[[Soft tissue sarcoma|Soft tissue sarcoma (STS)]]
 +
|style="background-color:#deebf7"|[[Alveolar soft part sarcoma|Alveolar soft part sarcoma (ASPS)]]
 +
|style="background-color:#deebf7"|[[Dermatofibrosarcoma protuberans]]
 +
|style="background-color:#deebf7"|[[Desmoid tumor]]
 +
|-
 +
|style="background-color:#deebf7"|[[Epithelioid sarcoma]]
 
|style="background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
 
|style="background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
−
|style="background-color:#deebf7"|[[Osteosarcoma]]
+
|style="background-color:#deebf7"|[[Inflammatory myofibroblastic tumor|Inflammatory myofibroblastic tumor (IMT)]]
 +
|style="background-color:#deebf7"|[[Leiomyosarcoma|Leiomyosarcoma (LMS)]]
 +
|-
 +
|style="background-color:#deebf7"|[[Liposarcoma]]
 +
|style="background-color:#deebf7"|[[PEComa]]
 +
|style="background-color:#deebf7"|[[Rhabdomyosarcoma|Rhabdomyosarcoma (RMS)]]
 +
|style="background-color:#deebf7"|[[Tenosynovial giant cell tumor|Tenosynovial giant cell tumor (TGCT)]]
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Rhabdomyosarcoma]]
+
|style="background-color:#deebf7"|[[Vascular sarcoma]]
−
|style="background-color:#deebf7"|[[Soft tissue sarcoma|Soft tissue sarcoma (STS)]]  
+
|style="background-color:#deebf7"|[[Angiosarcoma]]
−
|style="background-color:#deebf7"|[[Vascular sarcoma]]  
+
|style="background-color:#deebf7"|[[Kaposi sarcoma|Kaposi sarcoma (KS)]]
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Thoracic Oncology'''
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Thoracic Oncology'''
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Esophageal cancer]]
+
|style="background-color:#deebf7"|[[Non-small cell lung cancer | Non-small cell lung cancer (NSCLC)]]
−
|style="background-color:#deebf7"|[[Non-small cell lung cancer | Lung cancer, non-small cell (NSCLC)]]
+
|style="background-color:#deebf7"|[[Non-small cell lung cancer, nonsquamous|NSCLC, nonsquamous]]
 +
|style="background-color:#deebf7"|[[Non-small cell lung cancer, squamous|NSCLC, squamous]]
 
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_ALK-positive|NSCLC, ALK-positive]]
 
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_ALK-positive|NSCLC, ALK-positive]]
 +
|-
 
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_BRAF-mutated|NSCLC, BRAF-mutated]]
 
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_BRAF-mutated|NSCLC, BRAF-mutated]]
−
|-
 
 
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_EGFR-mutated|NSCLC, EGFR-mutated]]
 
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_EGFR-mutated|NSCLC, EGFR-mutated]]
 +
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_HER2-mutated|NSCLC, HER2-mutated]]
 
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_KRAS-mutated|NSCLC, KRAS-mutated]]
 
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_KRAS-mutated|NSCLC, KRAS-mutated]]
 +
|-
 
|style="background-color:#deebf7"|[[Non-small cell lung cancer, MET-mutated|NSCLC, MET-mutated]]
 
|style="background-color:#deebf7"|[[Non-small cell lung cancer, MET-mutated|NSCLC, MET-mutated]]
 
|style="background-color:#deebf7"|[[Non-small cell lung cancer, RET-positive|NSCLC, RET-positive]]
 
|style="background-color:#deebf7"|[[Non-small cell lung cancer, RET-positive|NSCLC, RET-positive]]
 +
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_ROS1-positive|NSCLC, ROS1-positive]]
 +
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_CNS_metastases|NSCLC, CNS metastases]]
 
|-
 
|-
−
|style="background-color:#deebf7"|[[Non-small_cell_lung_cancer,_ROS1-positive|NSCLC, ROS1-positive]]
+
|style="background-color:#deebf7"|[[Small cell lung cancer |Small cell lung cancer (SCLC)]]
−
|style="background-color:#deebf7"|[[Small cell lung cancer | Lung cancer, small cell (SCLC)]]
 
−
|style="background-color:#deebf7"|[[Mesothelioma]]
 
 
|style="background-color:#deebf7"|[[Thymoma]]
 
|style="background-color:#deebf7"|[[Thymoma]]
 +
|style="background-color:#deebf7"|
 +
|style="background-color:#deebf7"|
 
|-
 
|-
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Site-agnostic'''
 
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Site-agnostic'''
Line 182: Line 226:
 
|-
 
|-
 
|style="background-color:#deebf7"|[[MSI-H or dMMR]]
 
|style="background-color:#deebf7"|[[MSI-H or dMMR]]
 +
|style="background-color:#deebf7"|[[NTRK]]
 +
|style="background-color:#deebf7"|[[RET]]
 
|style="background-color:#deebf7"|[[SMO or PTCH-1 (Hedgehog)]]
 
|style="background-color:#deebf7"|[[SMO or PTCH-1 (Hedgehog)]]
 +
|-
 
|style="background-color:#deebf7"|[[TMB-H]]
 
|style="background-color:#deebf7"|[[TMB-H]]
−
|style="background-color:#deebf7"|[[Adenocarcinoma of unknown primary]]
+
|style="background-color:#deebf7"|[[Carcinoma of unknown primary|Carcinoma of unknown primary (CUP)]]
−
|-
 
−
|style="background-color:#deebf7"|[[NET of unknown primary]]
 
−
|style="background-color:#deebf7"|[[SCC of unknown primary]]
 
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
Line 194: Line 238:
 
|}
 
|}
 
<span id="malignantheme"></span>
 
<span id="malignantheme"></span>
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
 
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#de2d26"| '''Malignant Hematology'''
 
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#de2d26"| '''Malignant Hematology'''
Line 206: Line 247:
 
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, FLT3-positive | AML, FLT3-positive]]
 
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, FLT3-positive | AML, FLT3-positive]]
 
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, IDH-mutated | AML, IDH-mutated]]
 
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, IDH-mutated | AML, IDH-mutated]]
 +
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, NPM1-mutated | AML, NPM1-mutated]]
 +
|-
 
|style="width: 25%; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
 
|style="width: 25%; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
−
|-
 
 
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
 
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
 
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia, Ph-positive | B-ALL, Ph+]]
 
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia, Ph-positive | B-ALL, Ph+]]
 
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]]
 
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]]
−
|style="background-color:#fee0d2"|[[Blastic plasmacytoid dendritic cell neoplasm]]
 
 
|-
 
|-
 +
|style="background-color:#fee0d2"|[[Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm (BPDCN)]]
 
|style="background-color:#fee0d2"|[[CNS leukemia]]
 
|style="background-color:#fee0d2"|[[CNS leukemia]]
−
|style="background-color:#fee0d2"|
 
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
Line 220: Line 261:
 
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
 
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[Chronic myelogenous leukemia | Chronic myelogenous leukemia (CML)]]
+
|style="background-color:#fee0d2"|[[Chronic myeloid leukemia | Chronic myeloid leukemia (CML)]]
 
|style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
 
|style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
 
|style="background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
 
|style="background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
 
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
 
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[Myelodysplastic syndrome]]
+
|style="background-color:#fee0d2"|[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]
 
|style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis]]
 
|style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis]]
 
|style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]]
 
|style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]]
Line 233: Line 274:
 
|-
 
|-
 
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
 
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
 +
|style="background-color:#fee0d2"|[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]]
 
|style="background-color:#fee0d2"|[[CNS lymphoma]]
 
|style="background-color:#fee0d2"|[[CNS lymphoma]]
 
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
 
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
 +
|-
 +
|style="background-color:#fee0d2"|[[High-grade B-cell lymphoma]]
 
|style="background-color:#fee0d2"|[[HIV-associated lymphoma]]
 
|style="background-color:#fee0d2"|[[HIV-associated lymphoma]]
−
|-
 
−
|style="background-color:#fee0d2"|[[Hodgkin lymphoma|Hodgkin lymphoma (HL)]]
 
 
|style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
 
|style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
 
|style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
 
|style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
 +
|-
 
|style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
 
|style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
−
|-
 
 
|style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
 
|style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
−
|style="background-color:#fee0d2"|
 
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
Line 263: Line 304:
 
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
 
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
 
|style="background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (main page)]]
 
|style="background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (main page)]]
−
|style="background-color:#fee0d2"|[[Multiple_myeloma,_induction|MM, induction]]
+
|style="background-color:#fee0d2"|[[Multiple_myeloma,_induction|MM,]] induction
−
|style="background-color:#fee0d2"|[[Multiple_myeloma,_consolidation_and_maintenance|MM, consolidation & maintenance]]
+
|style="background-color:#fee0d2"|[[Multiple_myeloma,_consolidation_and_maintenance|MM, consolidation &]] maintenance
 
|-
 
|-
 
|style="background-color:#fee0d2"|[[Multiple_myeloma,_relapsed-refractory|MM, relapsed/refractory]]
 
|style="background-color:#fee0d2"|[[Multiple_myeloma,_relapsed-refractory|MM, relapsed/refractory]]
−
|style="background-color:#fee0d2"|[[Plasma cell leukemia]]
+
|style="background-color:#fee0d2"|[[Plasma cell leukemia|Plasma cell leukemia (PCL)]]
 
|style="background-color:#fee0d2"|[[POEMS syndrome]]
 
|style="background-color:#fee0d2"|[[POEMS syndrome]]
 
|style="background-color:#fee0d2"|[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]]
 
|style="background-color:#fee0d2"|[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]]
Line 293: Line 334:
 
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
 
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
 
|-
 
|-
−
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocyte disorders'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocytic disorders'''
 
|-
 
|-
−
|style="background-color:#fee0d2"|[[Erdheim-Chester disease]]
+
|style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]]
 
|style="background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]]
 
|style="background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]]
−
|style="background-color:#fee0d2"|[[Langerhans cell histiocytosis]]
+
|style="background-color:#fee0d2"|[[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]]
 
|style="background-color:#fee0d2"|[[Rosai-Dorfman-Destombes disease]]
 
|style="background-color:#fee0d2"|[[Rosai-Dorfman-Destombes disease]]
 
|-
 
|-
 
|}
 
|}
−
<span id="transplant"></span>
+
<span id="peds"></span>
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
 
 +
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 +
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#ba871a"|'''Pediatric Neoplasms'''
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric CNS malignancies'''
 +
|-
 +
|style="width: 25%; background-color:#e8d7b3"|[[Low-grade glioma, pediatric|Low-grade glioma]]
 +
|style="width: 25%; background-color:#e8d7b3"|[[High-grade glioma, pediatric|High-grade glioma]]
 +
|style="width: 25%; background-color:#e8d7b3"|[[Medulloblastoma]]
 +
|style="width: 25%; background-color:#e8d7b3"|
 +
|-
 +
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric hematologic neoplasms'''
 +
|-
 +
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric | B-cell acute lymphoblastic leukemia (B-ALL)]]
 +
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric, Ph-positive | B-ALL, Ph+]]
 +
|style="background-color:#e8d7b3"|[[T-cell acute lymphoblastic leukemia, pediatric | T-cell acute lymphoblastic leukemia (T-ALL)]]
 +
|style="background-color:#e8d7b3"|[[Acute myeloid leukemia, pediatric | Acute myeloid leukemia (AML)]]
 
|-
 
|-
−
|[[#top|back to top]]
+
|style="background-color:#e8d7b3"|[[Anaplastic large cell lymphoma, pediatric | Anaplastic large cell lymphoma (ALCL)]]
−
|}
+
|style="background-color:#e8d7b3"|[[Chronic myeloid leukemia, pediatric | Chronic myeloid leukemia (CML)]]
−
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
+
|style="background-color:#e8d7b3"|[[Juvenile myelomonocytic leukemia | Juvenile myelomonocytic leukemia (JMML)]]
−
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#4a1486"|'''Cross-Disciplinary'''
+
|style="background-color:#e8d7b3"|
 
|-
 
|-
−
|colspan="4" style="font-size:125%; background-color:#9e9ac8"|'''Pediatric Oncology'''
+
|style="background-color:#e8d7b3"|[[Classical Hodgkin lymphoma, pediatric |Classical Hodgkin lymphoma (cHL)]]
 +
|style="background-color:#e8d7b3"|[[Non-Hodgkin lymphoma, pediatric | Non-Hodgkin lymphoma (NHL)]]
 +
|style="background-color:#e8d7b3"|
 +
|style="background-color:#e8d7b3"|
 
|-
 
|-
−
|style="background-color:#efedf5"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
+
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric solid tumors'''
−
|style="background-color:#efedf5"|[[B-cell acute lymphoblastic leukemia, Ph-positive | B-ALL, Ph+]]
 
−
|style="background-color:#efedf5"|[[Ewing sarcoma]]
 
−
|style="background-color:#efedf5"|[[Hepatoblastoma]]
 
 
|-
 
|-
−
|style="background-color:#efedf5"|[[Medulloblastoma]]
+
|style="background-color:#e8d7b3"|[[Epithelioid sarcoma]]
−
|style="background-color:#efedf5"|[[Neuroblastoma]]
+
|style="background-color:#e8d7b3"|[[Ewing sarcoma, pediatric|Ewing sarcoma]]
−
|style="background-color:#efedf5"|[[Osteosarcoma]]
+
|style="background-color:#e8d7b3"|[[Hepatoblastoma]]
−
|style="background-color:#efedf5"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]]
+
|style="background-color:#e8d7b3"|[[Neuroblastoma]]
 
|-
 
|-
−
|style="background-color:#efedf5"|[[Wilms tumor]]
+
|style="background-color:#e8d7b3"|[[Osteosarcoma, pediatric|Osteosarcoma]]
−
|style="background-color:#efedf5"|
+
|style="background-color:#e8d7b3"|[[Rhabdomyosarcoma, pediatric|Rhabdomyosarcoma]]
−
|style="background-color:#efedf5"|
+
|style="background-color:#e8d7b3"|[[Wilms tumor]]
−
|style="background-color:#efedf5"|
+
|style="background-color:#e8d7b3"|
 
|-
 
|-
−
|colspan="4" style="font-size:125%; background-color:#9e9ac8"|'''Transplant'''
+
|}
 +
<span id="transplant"></span>
 +
 
 +
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 +
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#4a1486"|'''Transplant and Immune Effector Cells (IECs)'''
 
|-
 
|-
 
|style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]]
 
|style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]]
 
|style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT]]
 
|style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT]]
 
|style="width: 25%; background-color:#efedf5"|[[Autologous HSCT]]
 
|style="width: 25%; background-color:#efedf5"|[[Autologous HSCT]]
−
|style="width: 25%; background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]]
+
|style="width: 25%; background-color:#efedf5"|[[Chimeric antigen receptor T cells (CAR-T)]]
 +
|-
 +
|style="background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]]
 +
|style="background-color:#efedf5"|[[Hepatic veno-occlusive disease|Hepatic veno-occlusive disease (VOD/SOS)]]
 +
|style="background-color:#efedf5"|
 +
|style="background-color:#efedf5"|
 
|-
 
|-
 
|}
 
|}
 
<span id="classicalheme"></span>
 
<span id="classicalheme"></span>
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
 
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
 
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Classical Hematology'''
 
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Classical Hematology'''
Line 345: Line 408:
 
|-
 
|-
 
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]]
−
|style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome]]
+
|style="width: 25%; background-color:#e5f5e0"|[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]]
 +
|style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]]
 +
|style="width: 25%; background-color:#e5f5e0"|[[Congenital thrombotic thrombocytopenic purpura|Congenital thrombotic thrombocytopenic purpura (cTTP)]]
 +
|-
 
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]]
−
|-
 
 
|style="width: 25%; background-color:#e5f5e0"|[[Inherited coagulopathy]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Inherited coagulopathy]]
 
|style="background-color:#e5f5e0"|[[Inherited thrombophilia]]
 
|style="background-color:#e5f5e0"|[[Inherited thrombophilia]]
 +
|-
 +
|style="background-color:#e5f5e0"|[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]]
 
|style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]]
 
|style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]]
 +
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|
 
|-
 
|-
Line 366: Line 434:
 
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|
 
|-
 
|-
−
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders'''
+
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders and Hemoglobinopathies'''
 
|-
 
|-
 
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]]
 
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]]
−
|style="background-color:#e5f5e0"|[[Autoimmune hemolytic anemia|Autoimmune hemolytic anemia (AIHA)]]
+
|style="background-color:#e5f5e0"|[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]]
−
|style="background-color:#e5f5e0"|[[Cold agglutinin disease]]
+
|style="background-color:#e5f5e0"|[[Cold agglutinin disease|Cold agglutinin disease (CAD)]]
 
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]
 
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]
 
|-
 
|-
 +
|style="background-color:#e5f5e0"|[[Pyruvate kinase deficiency|Pyruvate kinase deficiency (PKD)]]
 +
|style="background-color:#e5f5e0"|[[Beta thalassemia]]
 
|style="background-color:#e5f5e0"|[[Sickle cell anemia]]
 
|style="background-color:#e5f5e0"|[[Sickle cell anemia]]
−
|style="background-color:#e5f5e0"|[[Thrombotic thrombocytopenic purpura|Thrombotic thrombocytopenic purpura (TTP)]]
 
−
|style="background-color:#e5f5e0"|
 
 
|style="background-color:#e5f5e0"|
 
|style="background-color:#e5f5e0"|
 
|-
 
|-
Line 388: Line 456:
  
 
Priorities of this project include:
 
Priorities of this project include:
 +
<section begin=goals />
 
*'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]].
 
*'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]].
−
*'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts/full articles).
+
*'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature (PubMed and direct links to the abstracts articles).
 
*'''[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
 
*'''[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
 
*'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
 
*'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
 
*'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens.
 
*'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens.
 +
<section end=goals />
  
 
Additional possibilities for this project may include:
 
Additional possibilities for this project may include:
Line 401: Line 471:
 
*Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
 
*Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
  
−
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as [http://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.
+
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as [https://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.
  
 
<br><inputbox>
 
<br><inputbox>

Latest revision as of 01:43, 26 June 2024


HemOnc.org - A Free Hematology/Oncology Reference

HemOnc.org is the largest freely available medical wiki of interventions, regimens, and general information relevant to the fields of hematology and oncology. Any healthcare professional can sign up to contribute; the accuracy and completeness of content is overseen by the Editorial Board. Heavily visited pages can be accessed directly from the menu on the left. If this is your first time visiting, please start with the the tutorial page, review our philosophy, or just start exploring!
Regimens: 5,262 Guidelines: 1,217 Studies: 6,769 References: 7,731
Solid Tumors Malignant Hematology Pediatrics Transplant & IEC Classical Hematology

Links to all main disease pages

Solid Tumors
Breast Oncology
Breast cancer Breast cancer, ER-positive Breast cancer, HER2-positive Breast cancer, ER and HER2 co-expressing
Breast cancer, triple negative (TNBC) Breast cancer, BRCA-mutated Breast cancer, PIK3CA-mutated
Dermatologic Oncology
Cutaneous BCC Cutaneous SCC Melanoma Melanoma, BRAF-mutated
Melanoma, KIT-mutated Melanoma, NRAS-mutated Merkel cell carcinoma (MCC) Uveal melanoma
Endocrine Oncology
Adrenocortical carcinoma Neuroendocrine tumor (NET) Neuroendocrine carcinoma (NEC) Pancreatic NET
Pheochromocytoma Thyroid cancer Differentiated thyroid cancer (DTC) Medullary thyroid cancer (MTC)
Thyroid cancer, BRAF-mutated Thyroid cancer, RET-positive
Gastrointestinal Oncology, Intestinal
Anal cancer Appendiceal tumor Colon cancer Colon cancer, RAS wild-type
Colorectal cancer (CRC) CRC, BRAF-mutated CRC, HER2-positive CRC, MSI-H or dMMR
CRC, RAS wild-type Esophageal cancer Esophageal adenocarcinoma Esophageal SCC
Gastric cancer Gastric cancer, HER2-positive Rectal cancer Small bowel adenocarcinoma
Gastrointestinal Oncology, Extraintestinal
Cholangiocarcinoma Gallbladder cancer Hepatocellular carcinoma (HCC) Periampullary adenocarcinoma
Pancreatic adenocarcinoma Pancreatic adenocarcinoma, BRCA-mutated Pancreatic NET
Genitourinary Oncology
Penile cancer Prostate cancer Prostate cancer, BRCA-mutated Testicular cancer
Renal cell carcinoma (RCC) Clear cell RCC (ccRCC) Non-clear cell RCC (nccRCC) Papillary RCC
Sarcomatoid RCC VHL-associated RCC
Urothelial carcinoma Bladder cancer Upper tract urothelial carcinoma (UTUC)
Gynecologic Oncology
Cervical cancer Endometrial cancer Gestational trophoblastic neoplasia Low-grade serous ovarian cancer (LGSOC)
Ovarian cancer Ovarian cancer, BRCA-mutated Vulvar cancer
Head & Neck Oncology
Head and neck cancer Nasopharyngeal carcinoma (NPC) HPV+ Oropharyngeal cancer
Mesothelioma
Malignant peritoneal mesothelioma (MPEM) Malignant pleural mesothelioma (MPM)
Neuro-Oncology
Anaplastic glioma Craniopharyngioma Glioblastoma (GBM) Low-grade glioma
Meningioma Subependymal giant cell astrocytoma (SEGA)
CNS carcinoma CNS leukemia CNS lymphoma CNS melanoma
Sarcoma
Bone sarcoma Ewing sarcoma Giant-cell tumor of bone Osteosarcoma
Soft tissue sarcoma (STS) Alveolar soft part sarcoma (ASPS) Dermatofibrosarcoma protuberans Desmoid tumor
Epithelioid sarcoma Gastrointestinal stromal tumor (GIST) Inflammatory myofibroblastic tumor (IMT) Leiomyosarcoma (LMS)
Liposarcoma PEComa Rhabdomyosarcoma (RMS) Tenosynovial giant cell tumor (TGCT)
Vascular sarcoma Angiosarcoma Kaposi sarcoma (KS)
Thoracic Oncology
Non-small cell lung cancer (NSCLC) NSCLC, nonsquamous NSCLC, squamous NSCLC, ALK-positive
NSCLC, BRAF-mutated NSCLC, EGFR-mutated NSCLC, HER2-mutated NSCLC, KRAS-mutated
NSCLC, MET-mutated NSCLC, RET-positive NSCLC, ROS1-positive NSCLC, CNS metastases
Small cell lung cancer (SCLC) Thymoma
Site-agnostic
BRAF EGFR ERBB2 (HER2) ERBB3 (HER3)
MSI-H or dMMR NTRK RET SMO or PTCH-1 (Hedgehog)
TMB-H Carcinoma of unknown primary (CUP)

Malignant Hematology
Acute leukemias
Acute myeloid leukemia (AML) AML, FLT3-positive AML, IDH-mutated AML, NPM1-mutated
Acute promyelocytic leukemia (APL) B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ T-cell acute lymphoblastic leukemia (T-ALL)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) CNS leukemia
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myeloid leukemia (CML) Chronic myelomonocytic leukemia (CMML) Essential thrombocythemia (ET) Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome (MDS) Primary & secondary myelofibrosis Polycythemia vera (PV) Systemic mastocytosis
Aggressive lymphomas
Burkitt lymphoma (BL) or Burkitt-like lymphoma Classical Hodgkin lymphoma (cHL) CNS lymphoma Diffuse large B-cell lymphoma (DLBCL)
High-grade B-cell lymphoma HIV-associated lymphoma Mantle cell lymphoma (MCL) Mediastinal gray-zone lymphoma (MGZL)
Primary mediastinal B-cell lymphoma (PMBL) Transformed lymphoma (TL)
Indolent lymphomas
Chronic lymphocytic leukemia (CLL/SLL) Follicular lymphoma (FL) Hairy cell leukemia (HCL) Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
MALT lymphoma Marginal zone lymphoma (MZL) Waldenström macroglobulinemia (WM/LPL)
Plasma cell dyscrasias
Light-chain (AL) amyloidosis Multiple myeloma (main page) MM, induction MM, consolidation & maintenance
MM, relapsed/refractory Plasma cell leukemia (PCL) POEMS syndrome Smoldering multiple myeloma (SMM)
T-cell and NK-cell neoplasms
Adult T-cell leukemia-lymphoma (ATLL) Anaplastic large cell lymphoma (ALCL) Cutaneous T-cell lymphoma (CTCL) Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT
Large granular lymphocytic (LGL) leukemia NK- and T-cell lymphoma (NKTCL) Peripheral T-cell Lymphoma (PTCL) T-cell acute lymphoblastic lymphoma (T-LBL)
T-cell prolymphocytic lymphoma (T-PLL)
Lymphoproliferative disorders
Castleman disease Post-transplant lymphoproliferative disorder (PTLD)
Histiocytic disorders
Erdheim-Chester disease (ECD) Hemophagocytic lymphohistiocytosis (HLH) Langerhans cell histiocytosis (LCH) Rosai-Dorfman-Destombes disease

Pediatric Neoplasms
Pediatric CNS malignancies
Low-grade glioma High-grade glioma Medulloblastoma
Pediatric hematologic neoplasms
B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ T-cell acute lymphoblastic leukemia (T-ALL) Acute myeloid leukemia (AML)
Anaplastic large cell lymphoma (ALCL) Chronic myeloid leukemia (CML) Juvenile myelomonocytic leukemia (JMML)
Classical Hodgkin lymphoma (cHL) Non-Hodgkin lymphoma (NHL)
Pediatric solid tumors
Epithelioid sarcoma Ewing sarcoma Hepatoblastoma Neuroblastoma
Osteosarcoma Rhabdomyosarcoma Wilms tumor

Transplant and Immune Effector Cells (IECs)
Stem cell mobilization Allogeneic HSCT Autologous HSCT Chimeric antigen receptor T cells (CAR-T)
Graft versus host disease (GVHD) Hepatic veno-occlusive disease (VOD/SOS)

Classical Hematology
Hemostasis and thrombosis
Acquired coagulopathy Acquired thrombotic thrombocytopenic purpura (aTTP) Antiphospholipid antibody syndrome (APLAS) Congenital thrombotic thrombocytopenic purpura (cTTP)
Heparin-induced thrombocytopenia (HIT) Hereditary hemorrhagic telangiectasia (HHT) Inherited coagulopathy Inherited thrombophilia
Thrombotic microangiopathy (TMA) Venous thromboembolism (VTE)
Cytopenias
Aplastic anemia Autoimmune cytopenia Immune thrombocytopenia (ITP) Thrombocytopenia in liver disease
WHIM syndrome
Hemolytic disorders and Hemoglobinopathies
Atypical hemolytic uremic syndrome (aHUS) Warm autoimmune hemolytic anemia (WAIHA) Cold agglutinin disease (CAD) Paroxysmal nocturnal hemoglobinuria (PNH)
Pyruvate kinase deficiency (PKD) Beta thalassemia Sickle cell anemia
Browse our complete index of pages

Additional Information

Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.

Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.

Priorities of this project include:

Additional possibilities for this project may include:

  • Creating synopses of pivotal clinical trials and regimens
  • Prioritizing regimens by their efficacy and/or toxicity
  • Capturing historical regimens that were standard-of-care prior to 2005
  • Checklists for common clinical scenarios/diseases
  • Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects

The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.


Retrieved from "https://hemonc.org/w/index.php?title=Main_Page&oldid=86694"